A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
A phase 2 trial of Capecitabine, Fluorouracil, Atezolizumab in colorectal cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05009069 by Hoffmann-La Roche, with 58 participants enrolled, started 2022-03-18 and due to reach its primary completion in 2023-11-21. Interventions recorded: Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab. Conditions listed: Rectal Neoplasms, Rectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Tiragolumab, Atezolizumab.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
- TechnologyPharmacogenomic testing before chemotherapy
Shares Fluorouracil (5-FU), Capecitabine.
- TreatmentDoxifluridine
Shares Fluorouracil (5-FU), Capecitabine, Colorectal cancer.
- TrialA Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Shares Capecitabine, Colorectal cancer.
- TrialA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel
Shares Tiragolumab, Roche / Genentech.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Roche / Genentech.